Navigation Links
Senhwa Biosciences Raises $17M Series B
Date:12/12/2013

SAN DIEGO and NEW TAIPEI CITY, Taiwan, Dec. 12, 2013 /PRNewswire-iReach/ -- Senhwa Biosciences, Inc. has raised an additional $17 million USD in a Series B financing to drive its anticancer agents through critical clinical trials, the company announced today. The Taiwan and San Diego, CA based company closed the round with participation from existing and new investors including H&Q Asia Pacific, Morningside and China Investment & Development Co., Ltd. Proceeds from the financing will be used to support the continuing development of its first-in-class anticancer agents CX-5461 and CX-4945 and take them through clinical proof-of-concept studies.

(Photo: http://photos.prnewswire.com/prnh/20131212/MN31456)

"Senhwa has made tremendous strides since its inception just one year ago. This round of funding will allow us to continue to advance and keeps us on course to open two new US-based Phase I and Phase II clinical trials during 2014," said Dr. Tai-Sen Soong, President of Senhwa Biosciences. "The level of commitment from new and existing investors reflects the quality of our assets, the confidence our investors have in our management team and it accelerates the development of Senhwa into a fully-fledged clinical development company."

Senhwa's lead anticancer compound for treating hematological malignancies is CX-5461, a p53 activating, Pol I inhibitor, currently in a Phase I clinical trial at the Peter MacCallum Cancer Centre in Melbourne, Australia. CX-5461 has a unique mechanism of action that enables selective activation of p53 in tumor cells but not in normal healthy ones, destroying malignant tissue while sparing the patient from the serious side effects associated with cancer therapies.

Senhwa's CK2 inhibitor, CX-4945, is being developed for combination treatment in solid tumors with the commonly used chemotherapy agents gemcitabine and cisplatin. Pre-clinically, combination of CX-4945 with these DNA damaging agents has been shown to act synergistically to enhance the efficacy of these anticancer treatments.

About Senhwa Biosciences

Senhwa Biosciences identifies and develops innovative therapies that have the potential to fundamentally change the way patients are treated. Our central philosophy is to unearth validated targets or therapies that could significantly improve treatment, but have not yet been properly exploited. As a value-added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through to clinical proof-of-concept.

Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global investigators and service providers. Clinical trials are ongoing or planned for Australia and the US, and our service providers work from their bases in North America, Asia, Australia and Europe.For more information on Senhwa and its programs, please visit http://www.senhwabiosciences.com/.

Media Contact: Sean O'Brien, Senhwa Biosciences, 858-552-6808, sobrien@senhwabio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Senhwa Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2019)... ANGELES (PRWEB) , ... November 15, 2019 , ... Cosmetic ... were performed in 2018. While patients continue to undergo cosmetic procedures all throughout the ... by the doctor or the facility, anesthesia fees and the extent of the work ...
(Date:11/15/2019)... ... ... Ahead of what’s expected to be among the most severe flu seasons ... Residences, Fulton County Commissioners Marvin Arrington, Jr. and Natalie Hall, as well as City ... residents ages 65 and older at Baptist Towers (1881 Myrtle Drive, SW, Atlanta, Ga. ...
(Date:11/14/2019)... ... 14, 2019 , ... Liv Foods, Inc. has signed a ... Starting January 2020, all five LivBar flavors will be available at all 23 ... hand-baked energy bar that has gained rapid traction in the market in the ...
Breaking Medicine Technology:
(Date:11/19/2019)... ANGELES (PRWEB) , ... November 19, 2019 , ... ... to announce an exclusive interview with Experience Ancient Seas Founder Lisa ... Seas is a company that creates mineral-rich products that nourish skin with eighty-four ...
(Date:11/19/2019)... Texas (PRWEB) , ... November 19, 2019 , ... ... practice solutions, is proud to announce Karna Morrow, CPC, RCC, CCS-P, as the ... healthcare industry. From leading electronic health record implementations, to providing consulting and training ...
(Date:11/19/2019)... ... November 18, 2019 , ... ... online B2B marketplaces for the scientific and healthcare industries, announced today the ... Business Marketing (previously known as Advantage Business Media) ceased operations after 13 ...
(Date:11/16/2019)... (PRWEB) , ... November 15, 2019 , ... ... adults living with memory impairment, has announced the Best Memory Care Facilities in ... to experts, facility features and amenities. , According to the Alzheimer’s ...
(Date:11/16/2019)... ... November 16, 2019 , ... Uniform Advantage (UA), was ... largest faith-based health systems, as it underwent its brand transition from Adventist Health ... product selection to fitting events to uniform delivery. The scope of the new ...
Breaking Medicine News(10 mins):